常用口服抗血小板药物不耐受及低反应性人群诊疗专家共识

2021-05-21 中国医师协会心血管内科医师分会 中华心血管病 杂志( 网络版),2021,4:e1000076.

由中国医师协会心血管内科医师分会、中国卒中学会和国际血管联盟中国分部发起,根据近年国内外动脉粥样硬化性疾病抗血小板治疗临床研究成果,结合我国临床现状和从业专家的临床经验制定此共识。希望通过本共识的制定

中文标题:

常用口服抗血小板药物不耐受及低反应性人群诊疗专家共识

发布日期:

2021-05-21

简要介绍:

由中国医师协会心血管内科医师分会、中国卒中学会和国际血管联盟中国分部发起,根据近年国内外动脉粥样硬化性疾病抗血小板治疗临床研究成果,结合我国临床现状和从业专家的临床经验制定此共识。希望通过本共识的制定与应用,为优化临床抗血小板药物不耐受及低反应性患者的诊疗提供指导。

相关资料下载:
[AttachmentFileName(sort=1, fileName=常用口服抗血小板药物不耐受及低反应性人群诊疗专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=975161c002115207, title=常用口服抗血小板药物不耐受及低反应性人群诊疗专家共识, enTitle=, guiderFrom=中华心血管病 杂志( 网络版),2021,4:e1000076., authorId=0, author=, summary=由中国医师协会心血管内科医师分会、中国卒中学会和国际血管联盟中国分部发起,根据近年国内外动脉粥样硬化性疾病抗血小板治疗临床研究成果,结合我国临床现状和从业专家的临床经验制定此共识。希望通过本共识的制定, cover=https://img.medsci.cn/2021624/1624538953801_2020535.jpg, journalId=0, articlesId=null, associationId=315, associationName=中国医师协会心血管内科医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Fri May 21 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>由中国医师协会心血管内科医师分会、中国卒中学会和国际血管联盟中国分部发起,根据近年国内外动脉粥样硬化性疾病抗血小板治疗临床研究成果,结合我国临床现状和从业专家的临床经验制定此共识。希望通过本共识的制定与应用,为优化临床抗血小板药物不耐受及低反应性患者的诊疗提供指导。</p> </div> </div> </div>, tagList=[TagDto(tagId=1124, tagName=抗血小板药物)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1124, guiderKeyword=抗血小板药物, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13777, appHits=299, showAppHits=0, pcHits=715, showPcHits=13474, likes=4, shares=36, comments=10, approvalStatus=1, publishedTime=Sat Jun 26 20:07:40 CST 2021, publishedTimeString=2021-05-21, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Thu Jun 24 20:49:22 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 22:26:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=常用口服抗血小板药物不耐受及低反应性人群诊疗专家共识.pdf)])
常用口服抗血小板药物不耐受及低反应性人群诊疗专家共识.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1193908, encodeId=bcba1193908ea, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:56:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181835, encodeId=e86b118183507, content=(好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42cf6453217, createdName=ms1000000489067778, createdTime=Fri Jan 07 13:47:07 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180219, encodeId=1f02118021956, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fa5708317, createdName=ms9000002102609454, createdTime=Mon Jan 03 23:11:06 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084867, encodeId=ac70108486e7b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77426425910, createdName=ms4000000713440894, createdTime=Mon Dec 27 21:08:37 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084442, encodeId=9a23108444200, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eb05376360, createdName=ms6000000489906423, createdTime=Sun Dec 26 18:07:47 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2022-02-16 龙珠

    学习好资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1193908, encodeId=bcba1193908ea, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:56:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181835, encodeId=e86b118183507, content=(好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42cf6453217, createdName=ms1000000489067778, createdTime=Fri Jan 07 13:47:07 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180219, encodeId=1f02118021956, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fa5708317, createdName=ms9000002102609454, createdTime=Mon Jan 03 23:11:06 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084867, encodeId=ac70108486e7b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77426425910, createdName=ms4000000713440894, createdTime=Mon Dec 27 21:08:37 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084442, encodeId=9a23108444200, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eb05376360, createdName=ms6000000489906423, createdTime=Sun Dec 26 18:07:47 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2022-01-07 ms1000000489067778

    (好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1193908, encodeId=bcba1193908ea, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:56:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181835, encodeId=e86b118183507, content=(好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42cf6453217, createdName=ms1000000489067778, createdTime=Fri Jan 07 13:47:07 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180219, encodeId=1f02118021956, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fa5708317, createdName=ms9000002102609454, createdTime=Mon Jan 03 23:11:06 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084867, encodeId=ac70108486e7b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77426425910, createdName=ms4000000713440894, createdTime=Mon Dec 27 21:08:37 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084442, encodeId=9a23108444200, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eb05376360, createdName=ms6000000489906423, createdTime=Sun Dec 26 18:07:47 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2022-01-03 ms9000002102609454

    好东西

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1193908, encodeId=bcba1193908ea, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:56:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181835, encodeId=e86b118183507, content=(好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42cf6453217, createdName=ms1000000489067778, createdTime=Fri Jan 07 13:47:07 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180219, encodeId=1f02118021956, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fa5708317, createdName=ms9000002102609454, createdTime=Mon Jan 03 23:11:06 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084867, encodeId=ac70108486e7b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77426425910, createdName=ms4000000713440894, createdTime=Mon Dec 27 21:08:37 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084442, encodeId=9a23108444200, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eb05376360, createdName=ms6000000489906423, createdTime=Sun Dec 26 18:07:47 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2021-12-27 ms4000000713440894

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1193908, encodeId=bcba1193908ea, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:56:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181835, encodeId=e86b118183507, content=(好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42cf6453217, createdName=ms1000000489067778, createdTime=Fri Jan 07 13:47:07 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180219, encodeId=1f02118021956, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79fa5708317, createdName=ms9000002102609454, createdTime=Mon Jan 03 23:11:06 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084867, encodeId=ac70108486e7b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77426425910, createdName=ms4000000713440894, createdTime=Mon Dec 27 21:08:37 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084442, encodeId=9a23108444200, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9eb05376360, createdName=ms6000000489906423, createdTime=Sun Dec 26 18:07:47 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2021-12-26 ms6000000489906423

    好资料

    0

拓展阅读

2016 稳定性冠心病口服抗血小板药物治疗中国专家共识

中国老年学学会心脑血管病专业委员会 · 2016-02-09

2021 WHO指南 关于预防先兆子痫的抗血小板药物的建议

世界卫生组织(WHO,The World Health Organization) · 2021-12-06

2022 ACG/CAG临床实践指南:急性胃肠道出血和内镜检查期间抗凝和抗血小板药物管理

美国胃肠病学院(ACG,American College of Gastroenterology) · 2022-03-17

心血管疾病患者发生消化道出血后抗血小板药物管理

北部战区总医院消化内科 · 2022-07-08